Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-1/programmed ligand-1 axis have significantly shifted the treatment paradigm in advanced NSCLC, clinical benefits of these agents are limited patients with EGFR-mutated NSCLC. Several predictive biomarkers (e.g., expression, tumor mutation burden), which been validated EGFR-wild type however, not efficacious tumors, suggesting unique characteristics microenvironment Here, we first summarized evidence on efficacy ICIs Then, cancer immunogram features NSCLC was depicted to visualize state cancer-immune system interactions, including foreignness, sensitivity effectors, metabolism, general status, infiltration, cytokines, and soluble molecules. We further discussed potential subpopulations EGFR mutations could benefit from ICI treatment. Lastly, put forward future strategies adequately maximize upcoming era combination immunotherapies.